Wells Fargo Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $105
Optimistic Buy Rating for Gilead Sciences: Anticipated EPS Growth and Strong Performance in 2024
RBC Capital Remains a Hold on Gilead Sciences (GILD)
Analysts Are Bullish on Top Healthcare Stocks: Gilead Sciences (GILD), Outset Medical (OM)
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $115
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $115
Morgan Stanley Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $113
Citi Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $125
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Gilead Sciences (GILD) and Abbott Laboratories (ABT)
Gilead Sciences: Supreme Court Case and New Innovations Drive Buy Rating
Bernstein Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $105
Bernstein Sticks to Its Buy Rating for Gilead Sciences (GILD)
Redburn Atlantic Adjusts Price Target on Gilead Sciences to $125 From $123, Keeps Buy Rating
Gilead Sciences Analyst Ratings
Morgan Stanley Upgrades Gilead Sciences(GILD.US) to Buy Rating, Raises Target Price to $113
Gilead Sciences: Buy Rating Backed by Promising Pipeline and Attractive Valuation
RBC Trims Price Target on Gilead Sciences to $83 From $84, Keeps Sector Perform Rating
Gilead Sciences' Buy Rating Affirmed on HIV Market Potential and Strategic Leadership Changes
Bernstein Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $105
Truist Financial Maintains Gilead Sciences(GILD.US) With Hold Rating